Chelation therapies: A chemical and biochemical perspective

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3658-3672

  Baran, E J ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Biological effects; Chelating agents; Chemical characteristics; Toxic metals

Indexed keywords

2,2 METHYLENE DI 8 QUINOLINOL; CADMIUM; CALCIUM; CHELATING AGENT; CLIOQUINOL; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIHYDROLIPOATE; DIMERCAPROL; EDETIC ACID; IRON; LEAD; MAGNESIUM; MANGANESE; MERCURY; METAL DERIVATIVE; PENICILLAMINE; SUCCIMER; THIOCTIC ACID; THORIUM; UNCLASSIFIED DRUG; UNITHIOL; URANIUM; VANADIUM; ZINC;

ALZHEIMER DISEASE; ARSENIC POISONING; ARTICLE; AUTOIMMUNE DISEASE; CHELATION THERAPY; COMPLEX FORMATION; DETOXIFICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; EXPERIMENTAL ANIMAL; HUMAN; HYPERTENSION; HYPOCALCEMIA; INJECTION SITE PAIN; INTOXICATION; IRON OVERLOAD; LEAD POISONING; LUNG TOXICITY; MERCURIALISM; NEPHRITIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT COMPLIANCE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

ANIMALS; CHELATING AGENTS; CHELATION THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IONS; LIGANDS; METALS;

EID: 78449264346     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213760     Document Type: Article

References (150)

1. Lippard, S.J.; Berg, J.M. Principles of Bioinorganic Chemistry, University Science Books, Mill Valley, CA, 1994.
2. Baran, E.J. Química Bioinorgánica, McGraw-Hill Interamericana de España S.A.; Madrid, 1995.
3. Roat-Malone, R.M. Bioinorganic Chemistry. A Short Course, J. Wiley, Hoboken, NJ, 2002.
4. Ewart, D.K.; Hughes, M.N. The extraction of metals from ores using bacteria. Adv. Inorg. Chem., 1991, 36, 103-35.
5. Reedijk, J.; Ed. Bioinorganic Catalysis, Marcel Dekker, New York, 1993.
6. Zocher, F.; Trautwein, H.; Riermeier, T.H.; Dingerdissen, U. Neue Wege in der Biokatalyse. Chem. unserer Zeit, 2001, 35, 238-49.
7. Mann, S. Biomineralization: a novel approach to crystal engineering. Endeavour, 1991, 15, 120-25.
8. Safinya, C.R.; Addadi, L. Biomaterials. Curr. Opin. Solid State Mater. Sci., 1996, 1, 387-91.
9. Mann, S.; Ed.; Biomimetic Materials Chemistry, VCH-Publishers, New York, 1996.
10. Sigel, H.; Ed.; Metal Ions in Biological Systems, Circulation of Metals in the Environment, Marcel Dekker, New York, 1984, Vol. 18.
11. Sigel, H.; Sigel, A.; Eds.; Metal Ions in Biological Systems, Degradation of Environmental Pollutants by Microorganisms and Their Metalloenzymes, Marcel Dekker, New York, 1992, Vol. 28.
12. th ed. Lewis Publishers, Boca Raton, 2000.
13. Guo, Z.; Sadler, P.J. Metals in medicine. Angew. Chem. Int. Ed. 1999, 38, 1512-31.
14. Sigel, H.; Ed. Metal Ions in Biological Systems, Inorganic Drugs in Deficiency and Disease, Marcel Dekker, New York, 1982, Vol. 14.
15. Gielen, M.F.; Ed. Metal-Based Anti-Tumor Drugs, Freund Publishing House Ltd.; London, 1988.
16. Farrell, N. Transition Metal Complexes as Drugs and Chemotherapeutic Agents, Kluwer, Dordrecht, 1989.
17. Farrell, N.P.; Ed. Uses of Inorganic Chemistry in Medicine, Royal Society of Chemistry, Cambridge, 1999.
18. Sadler, P.J. Inorganic chemistry and drug design. Adv. Inorg. Chem., 1991, 36, 1-48.
19. Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry. Chem. Rev. (special issue) 1999, 99, 2201-2842.
20. Frieden, E.; Ed. In Biochemistry of the Essential Ultratrace Elements, Plenum Press, New York, 1984, pp. 1-15.
21. Baran, E.J. Trace element supplementation: recent advances and perspectives. Mini Rev. Med. Chem. 2004, 4, 1-9.
22. Mertz, W. The essential trace elements. Science 1981, 213, 1332-38.
23. Merian, E.; Ed. Metalle in der Umwelt. Verteilung, Analytik und biologische Relevanz, Verlag Chemie, Weinheim, 1984.
24. Taylor, D.M.; Williams, D.R. Trace Element Medicine and Chelation Therapy, The Royal Society of Chemistry, Cambridge, 1995.
25. Aposhian, H.V.; Maiorino, R.M.; González-Ramírez, D.; ZunigaCharles, M.; Xu, Z.; Hurlbut, K.M.; Junco-Munoz, P.; Dart, R.C.; Aposhian, M.M. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology, 1995, 97, 23-38.
26. nd ed. Academic Press, San Diego, 1993.
27. Aaseth, J. Recent advances in the therapy of metal poisoning with chelating agents. Hum. Toxicol., 1983, 2, 257-72.
28. Howard-Lock, H.E.; Lock, C.J.L. In Comprehensive Coordination Chemistry, Wilkinson, G.; Gillard, R.D.; McCleverty, J.A.; Eds. Pergamon Press, Oxford, 1987, Vol. 6, pp. 755-78.
29. Andersen, O. Principles and recent development in chelation treatment of metal intoxication. Chem. Rev. 1999, 99, 2683-2710.
30. Andersen, O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev. Med. Chem. 2004, 4, 11-21.
31. Williams, R.J.P. Metal ions in biological catalysis. Pure Appl. Chem. 1982, 54, 1889-1904.
32. Domingo, J.L. Developmental toxicity of metal chelating agents. Reprod. Toxicol. 1998, 12, 499-510.
33. Nogueira, C.W.; Soares, F.A.; Bolzan, R.C.; Jacques-Silva, M.C.; Souza, D.O.; Rocha, J.B.T. Investigations into the mechanism of 2,3dimercatopropanol neurotoxicity. Neurochem. Res. 2000, 25, 1553-58.
34. Nogueira, C.W.; Rotta, L.N.; Tavares, R.G.; Diogo, O.; Rocha, J.B.T. BAL modulates glutamate transport in synaptosomes and synaptic vesicles from rat brain. NeuroReport 2001, 12, 511-14.
35. Emmanuelli, T.; Rocha, J.T.B.; Pereira, M.E.; Porciuncula, L.O. Morach, V.M.; Martins, A.F.; Souza, D.O. Effect of mercuric chloride intoxication and dimercaprol treatment on -aminolevulinate dehydratase from brain, liver and kidney of adult mice. Pharmacol. Toxicol. 1996, 79, 138-43.
36. Germuth, jr. F.G.; Eagle H. The efficacy of BAL (2,3dimercaptopropanol) in the treatment of experimental lead poisoning in rabbits. J. Pharmacol. Exp. Ther. 1948, 92, 397-410.
37. Santos, F.W. Rocha, J.B.T.; Nogueira, C.W. 2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3dimercaptosuccinic acid increase lead-induced inhibition of aminolevulinate dehydratase in vitro and ex vivo. Toxicol. In Vitro 2006, 20, 317-23.
38. Bermejo-Martínez, F.; Prieto-Bauzá, A. Aplicaciones Analíticas del AEDT y Similares, Imprenta del Seminario Conciliar, Santiago de Compostela, 1960.
39. Martell, A.E.; Smith, R.M. Critical Stability Constants, Plenum Press, New York, 1974, Vol. 1.
40. Martell, A.E.; Smith, R.M. Critical Stability Constants, Plenum Press, New York, 1982, Vol. 5.
41. Tandon, S.K.; Jain, V.K.; Mathur, A.K. Effect of metal chelators on excretion and tissue levels of essential trace elements. Environ. Res. 1984, 35, 237-45.
42. Khandelwal, S.; Kachru, D.N.; Tandon, S.K. Influence of metal chelators on metalloenzymes. Toxicol. Lett. 1987, 37, 213-19.
43. Ibim, S.E.; Trotman, J.; Musey, P.I.; Semafuko, W.E. Depletion of essential elements by calcium disodium EDTA treatment in the dog. Toxicology 1992, 73, 229-37.
44. Powell, J.J.; Burden, T.J.; Greenfield, S.M.; Taylor, P.D.; Thompson, R.P.H. Urinary excretion of essential metals following intravenous calcium disodium edentate: an estimate of free zinc and zinc status in man. J. Inorg. Biochem. 1999, 75, 159-65.
45. Hugenschmidt, S.; Planas-Bohne, F.; Taylor, D.M. On the toxicity of low doses of tetrasodium-ethylenediamine-tetraacetate (NaEDTA) in normal rat kidney (NRK) cells in culture. Arch. Toxicol. 1993, 67, 76-78.
46. Rozema, T.C. The protocol for the safe and effective administration of EDTA and other chelating agents for vascular disease, degenerative disease, and metal toxicity. J. Adv. Med. 1997, 10, 5-100.
47. Seaton, C.L.; Lasman, J.; Smith D.R. The effects of CaNa2EDTAon brain lead mobilization in rdents determined using a stable lead isotope tracer. Toxicol. Appl. Pharmacol. 1999, 159, 153-60.
48. Flora, S.J.S.; Saxena, G. Mehta, A. REversal of lead-induced neuronal apoptosis by chelation treatment in rats: role of ROS and intracellular Ca(II). J. Pharmacol. Exp. Ther. 2007, 322, 108-16.
49. nd ed. Hampton Roads Publish. Co.; Charlottesville, VA, 2001.
50. Duffield, J.R.; May, P.M.; Williams, D.R. Computer simulation of metal ion equilibria in biofluids.IV. Plutonium speciation in human blood plasma and chelation therapy using polyaminopolycarboxylic acids. J. Inorg. Biochem. 1984, 20, 199-214.
51. Klimmek, R.; Krettek, C.; Werner, H.W. Acute effects of the heavy metal antidotes DMPS and DMSA on circulation, respiration, and blood homeostasis in dogs. Arch. Toxicol. 1993, 67, 428-34.
52. Reichl, F.X.; Kreppel, H.; Szinicz, L.; Mücker, H. Fichtl, B.; Forth, W. Effect of various antidotes on the biliary and intestinal excretion of arsenic in situ and into the feces in vivo in guinea-pigs after injection of As2O3. Arch. Toxicol. 1994, 69, 35-8.
53. Porru, S.; Alessio, L. The use of chelating agents in occupational lead poisoning. Occup. Med. 1996, 46, 41-8.
54. De la Torre, A.; Bellés, M.; Llobet, J.M.; Mayayo, E.; Domingo, J.L. Comparison of the effectiveness of 2,3-dimercaptopropanol (BAL) and meso-2,3-dimercaptosuccinic acid (DMSA) as protective agents against mercuric chloride-induced nephrotoxicity in rats. Biol. Trace Elem. Res. 1996, 63, 1-10.
55. Aposhian, M.M.; Maoiorino, R.M.; Xu, Z.; Aposhian, H.V. Sodium 2,3dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats. Toxicology 1996, 109, 49-55.
56. Nogueira, C.W.; Soares, F.A.; Nascimento, P.C.; Muller, D.; Rocha, J.B.T. 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3dimercaptosuccinic acid increase mercuryand cadmiuminduced inhibition of -aminolevulinate dehydratase. Toxicology 2003, 184, 85-95.
57. Nogueira, C.W.; Santos, F.W.; Soares, F.A.; Rocha, J.B.T. 2,3dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid and meso2,3-dimercaptosuccinic acid inhibit -aminolevulinate dehydratase from human erythrocytes in vitro. Environm. Res. 2004, 94, 254-61.
58. Kalia, K.; Flora, S.J.S. Strategies for the safe and effective therapeutic measures for chronic arsenic and lead poisoning. J. Occup. Health 2005, 47, 1-21.
59. Jones, M.M.; Singh, P.K.; Gale, G.R.; Smith, A.B.; Atkins, L.M. Cadmium mobilization in vivo by intraperitoneal administration of monoalkyl esters of meso-2,3-dimercaptosuccinic acid in mice. Toxicology 1992, 70, 336-43.
60. Gale, G.R.; Smith, A.B.; Jones, M.M.; Singh, P.K. Meso-2,3dimercaptosuccinic acid monoalkyl esters: effects on mercury levels in mice. Toxicology 1993, 81, 49-56.
61. Xu, C.; Holscher, M.A.; Jones, M.M.; Singh, P.K. Effects of monoisoamyl meso-2,3-dimercaptosuccinate on the pathology of acute cadmium intoxication. Toxicol. Environ. Health 1995, 45, 261-77.
62. Flora, S.J.S.; Bhadauria, S.; Kannan G.M.; Singh, N. Arsenic induced oxidative stress and role of antioxidant supplementation during chelation: A review. J. Environ. Biol. 2007, 28, 333-47.
63. Mishra, D. Flora, S.J.S. Quercitin administration during chelation therapy protects arsenic-induced oxidative stress in mice. Biol. Trace Elem. Res. 2008, 122, 137-47.
64. nd ed. Pharmaceutical Press, London, 2001.
65. Petersen Shay, K.; Moreau, R.F.; Smith, E.J.; Smith, A.R.; Hagen, T.M. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 2009, 1790, 1149-60.
66. Navari-Izzo, F.; Quartacci, M.F.; Sgherri, C. Lipoic acid: a unique antioxidant in the detoxification of activated oxygen species. Plant Physiol. Biochem. 2002, 40, 463-70.
67. Biwenga, G.Ph.; Haenen, G.R.M.M.; Bast, A. The Pharmacology of the antioxidant lipoic acid. Gen. Pharm. 1997, 29, 315-31.
68. Packer, L.; Wit, E.H.; Tritschler, H.J. Free Radic. Biol. Med. 1995, 19, 227-50.
69. Rooney, J.P.K. The roles of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of mercury. Toxicology, 2007, 234, 145-56.
70. 2+ in solution. Arch. Biochem. Biophys. 1978, 187, 208-14.
71. Sigel, H. Die hydrophoben und Metallionen-koordinierenden Eigenschaften von -Liposäure: ein Beispiel für intramolekulare Gleichgewichte in Metallionen-Komplexen. Angew. Chem. 1982, 94, 421-32.
72. Brown, P.B.; Edwards, J.O. The reaction of 1,3-dimercaptopropane, lipoic acid, and dihydrolipoic acid with metal ions. J. Inorg. Nucl. Chem. 1970, 32, 2671-75.
73. Bonomi, F.; Pagani, S.; Cariati, F.; Pozzi, A.; Crisponi, G.; Cristiani, F.; Diaz, A.; Zanoni, R. Synthesis and characterization of metal derivatives of dihydrolipoic acid and dihydrolipoamide. Inorg. Chim. Acta 1992, 192, 237-42.
74. 2+ toxicity in isolated hepatocytes. Biochim. Biophys. Acta 1990, 1052, 386-91.
75. Ou, P.; Tritschler, H.J.; Wolff, S.P. Thioctic (lipoic) acid; a therapeutic metal-chelating antioxidant? Biochem. Pharmacol. 1995, 50, 123-26.
76. Bonomi, F.; Pagani, S. Renoval of ferritin-bound iron by DLdihydrolipoate and DL-dihydrolipoamide. Eur. J. Biochem. 1986, 155, 295-300.
77. Lodge, J.K.; Traber, M.G.; Packer, L. Thiol chelation of Cu2+ by dihydrolipoic acid prevents human low density lipoprotein peroxidation. Free Radic. Med. Biol. 1998, 25, 287-97.
78. Gurer, H.; Ozgunes, H.; Oztezcan, S.; Ercal, N. Antioxidant role of -lipoic acid in lead toxicity. Free Radic. Biol. Med. 1999, 27, 75-81.
79. Gurer, H.; Ercal, N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic. Biol. Med. 2000, 29, 927-45.
80. Gregus, Z.; Stein, A.F.; Varga, F.; Klaassen, C.D. Effect of lipoic acid on biliary excretion of glutathione and metals. Toxicol. Appl. Pharmacol. 1992, 114, 88-96.
81. Coleman, M.D.; Eason, R.C.; Bailey, C.J. The therapeutic use of lipoic acid in diabetes: a current perspective. Env. Toxicol. Pharmacol. 2001, 10, 167-72.
82. Packer, L.; Tritschler, H.J.; Wessel, K. Neuroprotection by the metabolic antioxidant -lipoic acid. Free Radic. Biol. Med. 1997, 22, 359-78.
83. Ruprecht, J. Dimaval. Wissenschaftliche Produktmonographie. 7th ed. Heyl GmbH & Co. K.G.; Berlin, 2008.
84. Flora, G.J.S.; Kumar, P.; Seth, P.K. Recovery from lead induced biochemical and immunological alterations following combined treatment with DMSA and calcium disodium EDTA in rats. Environm. Toxicol. Pharmacol. 1998, 5, 127-134.
85. Saxena, G.; Pathak, U.; Flora, S.J.S. Beneficial role of monoesters of meso-2,3-dimercaptosuccinic acid in the mobilization of lead and recovery of tissue oxidative injury in rats. Toxicology 2005, 214, 39-56.
86. WHO: Environmental Health Criteria. 118. Inorganic Mercury. International Program on Chemical Safety, WHO, Geneva, 1991.
87. Guzzi, G.P.; La Porta, C.A.M. Molecular mechanisms triggered by mercury. Toxicology 2008, 244, 1-12.
88. Flora, S.J.S.; Pande, M.; Mehta, A. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. Chem.-Biol. Interact. 2003, 145, 267-280.
89. Nriagu, O.; Pirrone, N. Vanadium in the atmosphere. In Vanadium in the Environment, Part I: Chemistry and Biochemistry; Ed.: J.O.Nriagu, J. Wiley & Sons, New York, 1998; pp. 25-36.
90. Baran, V.; Baran, E.J. Contaminación atmosférica por vanadio: Importancia de su monitoreo y control. An. Acad. Nac. Cs. Ex. Fís. Nat. 2002, 54, 171-177.
91. Baran, E.J. La nueva farmacoterapia inorgánica. XVII. Compuestos de vanadio. Acta Farm. Bonaerense 1999, 16, 43-52.
92. Thompson, K.H.; Orvig, C. Design of vanadium compounds as insulin enhancing agents. J. Chem. Soc. Dalton Trans. 2000, 2885-2892.
93. Evangelou, A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42, 249-265.
94. Rehder, D. Biological and medicinal aspects of vanadium. Inorg. Chem. Comm. 2003, 6, 604-617.
95. Baran, E.J. Vanadium detoxification: Chemical and biochemical aspects. Chem. Biodivers. 2008, 5, 1475-1484.
96. Baran, E.J. Vanadium detoxification. In Vanadium in the Environment, Part II: Health Effects; Ed.: J.O.Nriagu, J. Wiley & Sons, New York, 1998; pp. 317-345.
97. Zümereoglu-Karan, B. The coordination chemistry of vitamin C. An overview. Coord. Chem. Rev. 2006, 250, 2295-2307.
98. Wilkins, P.C.; Johnson, M.D.; Holder, A.A.; Crans, D.C. Reduction of vanadium(V) by L-ascorbic acid at low and neutral pH: kinetic, mechanistic, and spectroscopic characterization. Inorg. Chem. 2006, 45, 1471-1479.
99. Ferrer, E.G.; Williams, P.A.M.; Baran, E.J. Interaction of the vanadyl(IV) cation with L-ascorbic acid and related systems. Z. Naturforsch. 1998, 53b, 256-262.
100. Ferrer, E.G.; Baran, E.J. Reduction of vanadium(V) with ascorbic acid and isolation of the generated oxovanadium(IV) species. Biol. Trace Elem. Res. 2001, 83, 111-119.
101. Williams, P.A.M.; Baran, E.J. On the interaction of vanadium species with meso-2,3-dimercaptosuccinic acid. Biol. Trace Elem. Res. 2006, 109, 189-194.
102. Williams, P.A.M.; Baran, E.J. Vanadium detoxification: On the interaction of oxovanadium(IV) and other vanadium species with 2,3-dimercapto-1propanesulfonate. J. Inorg. Biochem. 2008, 102, 1195-1198.
103. Williams, P.A.M.; Zinczuk, J.; Baran, E.J. On the interaction of vanadium species with the monoisoamyl ester of meso-2,3dimercaptosuccinic acid. Biol. Trace Elem. Res. 2010, 134, 220-225.
104. Scott, L.E.; Orvig, C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem. Rev. 2009, 109, 4885-4910.
105. Sarkar, B. Treatment of wilson and menkes disease. Chem. Rev. 1999, 99, 2535-2544.
106. Danks, D.M. Copper and liver disease. Eur. J. Pediatr. 1991, 150, 142-148.
107. Sarkar, B. Copper transport and its defect in Wilson disease: characterization of the copper-binding domain of Wilson disease ATPase. J. Inorg. Biochem. 2000, 79, 187-191.
108. Brewer, G. Copper in medicine. Curr. Op. Chem. Biol. 2003, 7, 207-212.
109. Crisponi, G.; Nurchi, V.M.; Fanni, D.; Gerosa, C.; Nemolato, S.; Faa, G. Copper-related diseases: From chemistry to molecular pathology. Coord. Chem. Rev. 2010, in the press.
110. DiDonato, M.; Sarkar, B. Copper transport and its alterations in Menkes and Wilson diseases. Biochim. Biophys. Acta 1997, 1360, 3-16.
111. Birker, P.J.M.W.I.; Freeman, H.C. Structure, properties and function of a copper(I)-copper(II) complex pf D-penicillamine: pentathallium(I) μ8-chloro-dodeca(D-penicillinato)-octacuprate(I) hexacuprate(II) n hydrate. J. Am. Chem. Soc. 1977, 99, 6890-6899.
112. Chvapil, M.; Kielar, F. Liska, F.; Sihankova, A.; Brendel, K. Synthesis and evaluation of long-acting D-penicillamine derivatives. Connect. Tissue Res. 2005, 46, 242-250.
113. Rush, T.; Hjelmhaug, J.; Lobner, D. Effects of chelators on mercury, iron, and lead neurotoxicity in cortical culture. Neurotoxicology 2009, 30, 47-51.
114. Brewer, G.J.; Dick, R.D.; Yuzbasiyan-Gurkin, V.; Tankanow, R.; Young, A.B.; Kluin, K.J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch. Neurol. 1991, 48, 42-47.
115. Quagraine, E.K.; Georgakaki, I.; Coucouvanis, D. Reactivity and kinetic studies of (NH4)2(MoS4) in acidic aqueous solution: Possible relevance to the angiostatic function of the MoS42ligand. J. Inorg. Biochem. 2009, 103, 143-155.
116. Hoogenraad, T.U. In Handbook of Metal-Ligand Interactions in Biological Fluids, G. Berthon, Ed.; Marcel Dekker, New York, 1995, Vol. 2. pp. 1176-81.
117. Vasák, M.; Kägi, J.H.R. In Metal Ions in Biological Systems, H. Sigel, Ed.; Marcel Dekker, New York, 1983, Vol. 15, pp. 213-73.
118. Crichton, R.R. Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences, Wiley, Chichester, 2001.
119. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Ward, R.J.; Crichton, R.R. Evaluation of new iron chelators and their therapeutic potential. Inorg. Chim. Acta 2002, 339, 470-480.
120. Dobbin, P.S.; Hider, R.C. Iron chelation therapy. Chem. Brit. 1990, 26, 565-568.
121. Nick, H. Iron chelation, quo vadis? Curr. Opin. Chem. Biol. 2007, 11, 419-423.
122. Santos, M.A. Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications. Mono and combined ligand approaches. Coord. Chem. Rev. 2008, 252, 1213-1224.
123. Propper, R.D.; Shurin, S.B.; Nathan, D.G. Reassesment of the use of desferrioxamine B in iron overload. N. Engl. J. Med. 1976, 294, 1421-1423.
124. Konthoghiorghes, G.J. Comparativ efficacy and toxicity of desferrioxamine, deferirpone and other iron and aluminium chelating drugs. Toxicol. Lett. 1995, 80, 1-18.
125. Baran, E.J. La nueva farmacoterapia inorgánica. VII. Compuestos de hierro. Acta Farm. Bonaerense 1988, 7,33-39.
126. Hoffbrand, A.V. Deferiprone therapy for transfusional iron overload. Best Pract. Res. Clin. Haematol. 2005, 18, 299-317.
127. Dobbin, P.S.; Hider, R.C.; Hall, A.D.; Taylor, P.D.; Sarpong P.; Porter, J.B.; Xiao, G.; van der Helm, D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3hydroxy-4(1H)pyridinones: Orally active iron chelators with clinical potential. J. Med. Chem. 1993, 36, 2448-2458.
128. Tanner, M.A.; Galanello, R.; Dessi, C.; Smith, G.C.; Westwood, M.A.; Agus, A.; Roughton, M.; Assomull, R.; Nair, S.V. Walker, J.M.; Pennell, D. A randomized, placebo-controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. J. Circ. 2007, 115, 1876-1884.
129. Origa, R.; Bina, P.; Agus, A.; Crobu, G.; Defrais, E.; Dessi, C.; Leoni, G.B.; Muroni, P.P. Galanello, R. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005, 90, 1309-1314.
130. Kattamis, A.; Ladis, V.; Berdousi, H.; Kelekis, N.L. Alexopoulou, E.; Papasotiriou, I.; Drakaki, K.; Kaloumenou, I.; Galani, A.; Kattamis, C. Iron chelation treatment with combined therapy with deferirpone and deferioxamine: a 12-month trial. Blood Cells Mol. Dis. 2006, 36, 21-25.
131. Waalen, J.; Beutier, E. Hereditary hemochromatosis: screening and management. Curr. Hematol. Rep. 2006, 5, 34-40.
132. Gómez, M.; Esparza, J.L.; Domingo, J.L.; Singh, P.K.; Jones, M.M. Chelation therapy in aluminum-loaded rats: influence of age. Toxicology 1999, 137, 161-168.
133. Mason, J.M.; Kokkoni, N.; Stott, K.; Doig, A.J. Design strategies for antiamyloid agents. Curr. Opin. Struct. Biol. 2003, 13, 526-532.
134. Cuajungco, M.P.; Fagét, K.Y. Zinc takes the center stage: its paradoxical role in Alzheimer disease. Brain Res. Rev. 2003, 41, 44-56.
135. Rauk, A. The chemistry of Alzheimer's disease. Chem. Soc. Rev. 2009, 38, 2698-2715.
136. Bush, A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003, 26, 207-214.
137. Bush, A.I.; Tanzi, R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008, 5, 421-432.
138. Crichton, R.R.; Dexter, D.T.; Ward, R.J. Metal based neurodegenerative diseases From molecular mechanism to therapeutic strategies. Coord. Chem. Rev. 2008, 252, 1189-1199.
139. Faller, P.; Hureau, C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloidpeptide. Dalton Trans. 2009, 1080-1094.
140. Molina-Holgado, F.; Hider, R.C.; Gaeta, A.; Williams, R.; Francis, P. Metal ions and neurodegeneration. Biometals 2007, 20, 639-654.
141. Kozlowski, H.; Janicka-Klos, A.; Brasun, J.; Gaggelli E.; Valensin, D. Valensin, G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord. Chem. Rev. 2009, 253, 2665-2685.
142. Regland, S.; Lehmann, W.; Abedini, T.; Blennow, K.; Jonsson, M.; Karlsson, T.; Sjögren, M.; Wallin, A.; Xilinas, M.; Gottfries, C.G. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr. Cogn. Disord. 2001, 12, 408-414.
143. Ferrada, E.; Aancibia, V.; Loeb, B.; Norambuena, E.; Olea-Azar, C. Huidobro-Toro, J.P. Stoichiometry and condicional stability constants of Cu(II) or Zn(II) clioquinol complexes: Implications for Alzheimer's and Huntington's disease therapy. Neurotoxicology 2007, 28, 445-449.
144. Mancino, A.M.; Hindo, S.S.; Kochi, A.; Lim, M.H. Effects of clioquinol on metal-triggered amyloidaggregation revisited. Inorg. Chem. 2009, 48, 9596-9598.
145. Di Vaira, M.; Bazzicalupi, C.; Orioli, P.; Messori, L. Bruni, B.; Zatta, P. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(II) and copper(II) complexes. Inorg. Chem. 2004, 43, 3795-3797.
146. Wagner, C.C.; Calvo, S.; Torre, M.H.; Baran, E.J. Vibrational spectra of clioquinol and its Cu(II) complex. J. Raman Spectr. 2007, 38, 373-376.
147. Deraeve, C.; Pitié, M.; Mazarguil, H.; Meunier, B. Bis-8hydroxyquinoline ligands as potential anti-Alzheimer agents. New J. Chem. 2007, 31, 193-195.
148. Zinczuk, J.; Piro, O.E.; Castellano, E.E.; Baran, E.J. Structural and spectroscopic characterization of 2,2'-methylenedi-8-quinolinol dichloride dihydrate. J. Mol. Struct. 2008, 802, 216-218.
149. Deraeve, C.; Boldron, C.; Maraval, A.; Mazarguil, H.; Gornitzka, H.; Vendier, L.; Pitié, M.; Meunier, B. Preparation and study of new poly-8hydroxyquinoline chelators for an anti-Alzheimer strategy. Chem. Eur. J. 2008, 14, 682-696.
150. Moret, V.; Laras, Y.; Pietrancosta, N.; Garino, C.; Quéléver, G.; Rolland, A.; Mallet, B.; Norreel, J.C.; Graus, J.L. 1,1'-Xylyl bis1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg. Med. Chem. Lett. 2006, 16, 3298-3301.